biphasic insulin aspart 30 + insulin aspart

**Biphasic insulin aspart 30 + insulin aspart** is a combination insulin therapy that includes biphasic insulin aspart 30 (BIAsp 30), which is itself a premixed formulation consisting of 30% rapid-acting insulin aspart and 70% intermediate-acting protamine-crystallized insulin aspart, plus additional rapid-acting insulin aspart. This combination is used to provide both rapid and intermediate glycemic control in patients with diabetes mellitus. Insulin aspart is a recombinant human insulin analog produced in *Saccharomyces cerevisiae*. The mechanism of action involves binding to the insulin receptor, activating its tyrosine kinase activity, and stimulating glucose uptake into tissues while inhibiting hepatic glucose production. The combination provides prandial and basal insulin coverage and may offer a simplified regimen compared to separate basal-bolus therapy[1][3][6].

Other names

biphasic insulin aspart 30/70 + insulin aspart